Cinclus Pharma Holding AB (publ)
Climate Impact & Sustainability Data (2024-01 to 2024-06)
Reporting Period: 2024-01 to 2024-06
Environmental Metrics
Social Achievements
- A new qualified share option program was approved at the annual general meeting. A total of 51,737 qualified share options were granted to the CEO, other management and specialists on April 9, 2024.
- A new share option program was approved at an extraordinary general meeting on June 3, 2024, conditional on Cinclus Pharma's ordinary shares being admitted to trading on Nasdaq Stockholm. A total of 290,000 share options were decided for the CEO and one of Cinclus Pharma's scientific advisors.
- A performance share program for employees in Cinclus Pharma was also decided.
Governance Achievements
- The company's share was listed on Nasdaq Stockholm on June 20, 2024.
Climate Goals & Targets
Environmental Challenges
- The company is dependent on further financing to be able to drive the development of linaprazan glurate further in the long term.
Mitigation Strategies
- The listing on Nasdaq Stockholm significantly reduced the refinancing risk. The company will continue to work with its financing strategy, which includes evaluating partners, lenders, or other financing opportunities to, for example, accelerate the development of linaprazan glurate by starting a second Phase III study earlier than planned or starting the H. pylori program in parallel with the eGERD program.